FDA - lift of clincial hold
Filed with ASX · · 1 page · English
InVert Graphite Limited on 6ix
Earlier from InVert Graphite
- Submission of IND amendments for Phase II study
- Completion of Manufacturing
- Appendix 4E - Preliminary Final Report
- Formation of Medical Advisory Board
- Shareholder Quarterly Update
Later from InVert Graphite
- Collaboration and IP option agreement with Monash University
- Phase II Clinical Trial - First Patient In
- Appendix 4C - December 2016 quarter
- Half Year Accounts
- Phase II clinical trial progress update
Follow InVert Graphite into a list and get an email when it puts out news.
Follow InVert Graphite